HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

proteoliposomes

erythrosomes are large proteoliposomes derived from crosslinked human erythrocyte cytoskeletons & exogenous lipid

Also Known As:

erythrosomes

Networked: 77 relevant articles (3 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Membrane Lipids: 1591
  - Proteolipids: 20
    - proteoliposomes: 77
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Proteolipids: 20
    - proteoliposomes: 77

Experts

1.	Ciancaglini, Pietro: 4 articles (12/2016 - 04/2006)
2.	Fernández, Luis E: 3 articles (01/2016 - 01/2011)
3.	Liguori, Lavinia: 3 articles (09/2015 - 01/2009)
4.	Cortes, Sandra: 2 articles (01/2017 - 09/2015)
5.	Lenormand, Jean-Luc: 2 articles (01/2017 - 09/2015)
6.	Baker, Aaron B: 2 articles (01/2016 - 01/2012)
7.	Cepeda, Meylán: 2 articles (01/2016 - 01/2012)
8.	de la Torre, Ana: 2 articles (01/2016 - 01/2012)
9.	Fernández, Sonsire: 2 articles (01/2015 - 01/2013)
10.	Clavell, Marilyn: 2 articles (01/2014 - 01/2011)

Related Diseases

1.	Ischemia 01/01/2023 - "Syndecan-4 proteoliposomes enhance revascularization in a rabbit hind limb ischemia model of peripheral ischemia." 01/31/2012 - "Using an animal model of limb ischemia, syndecan-4 proteoliposomes markedly improved the neovascularization following femoral artery ligation and recovery of perfusion of the ischemic limb. " 01/01/2023 - "Overall, our studies support that syndecan-4 proteoliposomes markedly enhance the therapeutic potential of growth factors in the context of disease and may be promising therapeutics for inducing vascular regeneration in peripheral ischemia. " 01/01/2023 - "In this work, we performed preclinical testing of an injectable formulation of syndecan-4 proteoliposomes combined with growth factors as treatment for peripheral ischemia delivered in an alginate hydrogel. "
2.	Wounds and Injuries (Trauma) 01/01/2016 - "We further demonstrated that co-therapy with syndecan-4 proteoliposomes enhanced wound closure in diabetic, hyperlipidemic ob/ob mice. " 01/01/2016 - "Together our findings support that syndecan-4 proteoliposomes markedly improve PDGF-BB efficacy for wound healing and may be useful in enhancing treatments for non-healing wounds. " 01/01/2016 - "Wounds treated with both syndecan-4 proteoliposomes and PDGF-BB had increased re-epithelization and angiogenesis in comparison to wounds treated with PDGF-BB alone. " 01/01/2016 - "Moreover, the wounds treated with syndecan-4 proteoliposomes and PDGF-BB also had increased M2 macrophages and reduced M1 macrophages, suggesting syndecan-4 delivery induces immunomodulation within the healing wounds. "
3.	Infertility (Sterility) 01/01/2020 - "The production of nano-erythrosomes (NEs) by extrusion, which is considered the "gold standard", has several disadvantages such as difficult equipment assembly, long procedure time, variable pressure, and problems with sterility. "
4.	Breast Neoplasms (Breast Cancer) 01/01/2011 - "Very small size proteoliposomes (VSSP) are a nanoparticulated adjuvant under investigation in clinical trials in patients with renal carcinoma, breast cancer, prostate cancer, and cervical intraepithelial neoplasia grade III. We found that VSSP adjuvant induced a significant splenomegaly due to accumulation of CD11b(+)Gr-1(+) cells. " 01/01/2016 - "The NGcGM3/VSSP vaccine, consisting in very small-sized proteoliposomes (VSSP) obtained by the incorporation of NGcGM3 into the outer membrane protein complex of Neisseria meningitidis, has been previously tested in a Phase II trial in patients with metastatic breast cancer (MBC) but emulsified with Montanide ISA 51. " 01/01/2014 - "While the NGcGM3/VSSP vaccine, a preparation consisting in very small sized proteoliposomes (VSSP) obtained by the incorporation of the NGcGM3 ganglioside into the outer membrane protein (OMP) complex of Neisseria meningitides, is currently studied in late stage clinical trials in breast cancer and melanoma patients, mechanisms involved in the vaccine's antitumor effect are insufficiently understood. "
5.	Prostatic Neoplasms (Prostate Cancer) 01/01/2011 - "Very small size proteoliposomes (VSSP) are a nanoparticulated adjuvant under investigation in clinical trials in patients with renal carcinoma, breast cancer, prostate cancer, and cervical intraepithelial neoplasia grade III. We found that VSSP adjuvant induced a significant splenomegaly due to accumulation of CD11b(+)Gr-1(+) cells. " 08/01/2016 - "In a previous study aimed to design a novel prostate cancer vaccine, the authors of the present study demonstrated the advantage of combining the adjuvants Montanide ISA 51 with very small size proteoliposomes (VSSP) to promote a significant humoral immune response to gonadotropin-releasing hormone (GnRH) in healthy animals. " 10/12/2012 - "Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer."

Related Drugs and Biologics

1.	Syndecan-4
2.	Becaplermin (PDGF-BB)
3.	Vaccines
4.	Membrane Proteins (Integral Membrane Proteins)
5.	montanide ISA 51
6.	Proteins (Proteins, Gene)
7.	Gonadotropin-Releasing Hormone (GnRH)
8.	Gangliosides
9.	Adenosine Triphosphatases (ATPase)
10.	Intercellular Signaling Peptides and Proteins (Growth Factors)

Related Therapies and Procedures

1.	Ligation
2.	Therapeutics
3.	Fluid Therapy (Oral Rehydration Therapy)
4.	Immunomodulation
5.	Investigational Therapies (Experimental Therapy)